A novel DC therapy with manipulation of MKK6 gene on nickel allergy in mice

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Watanabe, Megumi ^a   Ishimaru, Naozumi ^a   Ashrin, Meinar Nur ^a   Arakaki, Rieko ^a   Yamada, Akiko ^a   Ichikawa, Tetsuo ^a   Hayashi, Yoshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; NICKEL; SMALL INTERFERING RNA; MAP2K6 PROTEIN, MOUSE;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; DENDRITIC CELL; GENE; GENE OVEREXPRESSION; GENE TARGETING; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MKK6 GENE; MOUSE; NICKEL HYPERSENSITIVITY; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CONFOCAL MICROSCOPY; FEMALE; FLOW CYTOMETRY; GENETICS; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LANGERHANS CELL; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; FEMALE; FLOW CYTOMETRY; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; LANGERHANS CELLS; MAP KINASE KINASE 6; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NICKEL; RNA, SMALL INTERFERING;

EID: 79955536961     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019017     Document Type: Article

References (47)

1. Forte G, Petrucci F, Bocca B, (2008) Metal allergens of growing significance: epidemiology, immunotoxicology, strategies for testing and prevention. Inflamm Allergy Drug Targets 7: 145-162.
2. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF, (2009) Allergic and irritant contact dermatitis. Eur J Dermatol 19: 325-332.
3. Budinger L, Hertl M, (2000) Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview. Allergy 55: 108-115.
4. Martin SF, Jakob T, (2008) From innate to adaptive immune responses in contact hypersensitivity. Curr Opin Allergy Clin Immunol 8: 289-293.
5. Basketter DA, Briatico-Vangosa G, Kaestner W, Lally C, Bontinck WJ, (1993) Nickel, cobalt and chromium in consumer products: a role in allergic contact dermatitis? Contact Dermatitis 28: 15-25.
6. Aberer W, Holub H, Strohal R, Slavicek R, (1993) Palladium in dental alloys-the dermatologists' responsibility to warn? Contact Dermatitis 28: 163-165.
7. Rustemeyer T, von Blomberg BM, van Hoogstraten IM, Bruynzeel DP, Scheper RJ, (2004) Analysis of effector and regulatory immune reactivity to nickel. Clin Exp Allergy 34: 1458-1466.
8. Sinigaglia F, Scheidegger D, Garotta G, Scheper R, Pletscher M, et al. (1958) Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol 135: 3929-3932.
9. Kapsenberg ML, Wierenga EA, Stiekema FE, Tiggelman AM, Bos JD, (1992) Th1 lymphokine production profiles of nickel-specific CD4+T-lymphocyte clones from nickel contact allergic and non-allergic individuals. J Invest Dermatol 98: 59-63.
10. Moed H, Boorsma DM, Stoof TJ, von Blomberg BM, Bruynzeel DP, et al. (2004) Nickel-responding T cells are CD4+ CLA+ CD45RO+ and express chemokine receptors CXCR3, CCR4 and CCR10. Br J Dermatol 151: 32-41.
11. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
12. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
13. Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE, (2001) Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. Br J Dermatol 144: 523-532.
14. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU, (2005) T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. Toxicology 209: 101-107.
15. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, et al. (1995) Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 181: 2237-2247.
16. Lore K, Sonnerborg A, Spetz A L, Andersson U, Andersson J, (1998) Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells. J Immunol Methods 218: 173-187.
17. Riedl E, Stockl J, Majdic O, Scheinecker C, Knapp W, et al. (2000) Ligation of E-cadherin on in vitro-generated immature Langerhans-type dendritic cells inhibits their maturation. Blood 96: 4276-4284.
18. Geissmann F, Dieu-Nosjean MC, Dezutter C, Valladeau J, Kayal S, et al. (2002) Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 196: 417-430.
19. Villadangos JA, Cardoso M, Steptoe RJ, van Berkel D, Pooley J, et al. (2001) MHC class II expression is regulated in dendritic cells independently of invariant chain degradation. Immunity 14: 739-749.
20. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, et al. (1997) Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 158: 2919-2925.
21. Kyriakis JM, Avruch J, (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869.
22. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C, (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166: 3837-3845.
23. Jorgl A, Platzer B, Taschner S, Heinz LX, Hocher B, et al. (2007) Human Langerhans-cell activation triggered in vitro by conditionally expressed MKK6 is counterregulated by the downstream effector RelB. Blood 109: 185-193.
24. Nakae S, Naruse-Nakajima C, Sudo K, Horai R, Asano M, et al. (2001) IL-1 alpha, but not IL-1 beta, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. Int Immunol 13: 1471-1478.
25. Artik S, von Vultee C, Gleichmann E, Schwarz T, Griem P, (1999) Nickel allergy in mice: enhanced sensitization capacity of nickel at higher oxidation states. J Immunol 163: 1143-1152.
26. Black J, (1999) Allergic foreign body response. In: Biological performance of materials - Fundamentals of biocompatibility, 3rd edition. New York and Basel Marcel Dekker pp. 215-232.
27. Fields RC, Shimizu K, Mule JJ, (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 95: 9482-9487.
28. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811.
29. Nakahara T, Moroi Y, Uchi H, Furue M, (2006) Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 42: 1-11.
30. Toebak MJ, Gibbs S, Bruynzeel DP, Scheper RJ, Rustemeyer T, (2009) Dendritic cells: biology of the skin. Contact Dermatitis 60: 2-20.
31. Bennett CL, Noordegraaf M, Martina CA, Clausen BE, (2007) Langerhans cells are required for efficient presentation of topically applied hapten to T cells. J Immunol 179: 6830-6835.
32. Rincon M, Davis RJ, (2009) Regulation of the immune response by stress-activated protein kinases. Immunol Rev 228: 212-224.
33. Brown MD, Sacks DB, (2009) Protein scaffolds in MAP kinase signalling. Cell Signal 21: 462-469.
34. Boisleve F, Kerdine-Romer S, Pallardy M, (2005) Implication of the MAPK pathways in the maturation of human dendritic cells induced by nickel and TNF-alpha. Toxicology 206: 233-244.
35. Miyazawa M, Ito Y, Kosaka N, Nukada Y, Sakaguchi H, et al. (2008) Role of MAPK signaling pathway in the activation of dendritic type cell line, THP-1, induced by DNCB and NiSO4. J Toxicol Sci 33: 51-59.
36. Trompezinski S, Migdal C, Tailhardat M, Le Varlet B, Courtellemont P, et al. (2008) Characterization of early events involved in human dendritic cell maturation induced by sensitizers: cross talk between MAPK signalling pathways. Toxicol Appl Pharmacol 230: 397-406.
37. Schmidt M, Raghavan B, Muller V, Vogl T, Fejer G, et al. (2010) Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 11: 814-819.
38. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, et al. (2003) CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 171: 2571-2580.
39. Aiba S, Terunuma A, Manome H, Tagami H, (1997) Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur J Immunol 27: 3031-3038.
40. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, et al. (2000) Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 114: 295-302.
41. Van Waes C, (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082.
42. Kaisho T, Tanaka T, (2008) Turning NF-kappaB and IRFs on and off in DC. Trends Immunol 29: 329-336.
43. Ade N, Antonios D, Kerdine-Romer S, Boisleve F, Rousset F, et al. (2007) NF-kappaB plays a major role in the maturation of human dendritic cells induced by NiSO(4) but not by DNCB. Toxicol Sci 99: 488-501.
44. Antonios D, Ade N, Kerdine-Romer S, Assaf-Vandecasteele H, Larange A, et al. (2009) Metallic haptens induce differential phenotype of human dendritic cells through activation of mitogen-activated protein kinase and NF-kappaB pathways. Toxicol In Vitro 23: 227-234.
45. O'Neill D, Bhardwaj N, (2005) Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol Med 109: 1-18.
46. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ, (2008) Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev 222: 256-276.
47. Kinouchi N, Ohsawa Y, Ishimaru N, Ohuchi H, Sunada Y, et al. (2008) Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther 15: 1126-1130.